Chrissian AA, De Silva S, Quan M, Wiltchik E, Patel P, Furukawa B, Rogstad D, Rockwood N, Ho E, Cheek G. Utility of multimodal sampling and testing during advanced bronchoscopy for diagnosing atypical respiratory infections in a Coccidioides-endemic region. J Thorac Dis. 2023 Sep 1;15(9). doi: 10.21037/jtd-23-83
Clinch S, McDougall F, Barrett A, Olayinka-Amao B, Craveiro L, Baker M, Lindemann M. A patient-focused qualitative study to support content validity of digital performance assessments in MS. Poster presented at the 2021 ECTRIMS Annual Congress; October 13, 2021. [abstract] Mult Scler J Exp Transl Clin. 2021 Oct 21; 27(2 Suppl):329. doi: 10.1177/13524585211044667
Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020 Jan;9(2):1-14. doi: 10.1177/2055217320910778
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.